Change from baseline in BDI mean duration of study 14.3 weeks · pulmonary arterial hypertension
1 finding from 1 review
Mortality mean duration of study 30.2 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists showed no clear difference in mortality mean duration of study 30.2 weeks compared with placebo (low certainty).
1 finding from 1 review
Change from baseline in mean PAP (mmHg) mean duration of study 17.1 weeks · pulmonary arterial hypertension
1 finding from 1 review
Change from baseline in PVR (dyn/s/cm5) mean duration of study 15.7 weeks · pulmonary arterial hypertension
1 finding from 1 review
Hepatic toxicity mean duration of study 25 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists showed no clear difference in hepatic toxicity mean duration of study 25 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in WHO functional class · pulmonary arterial hypertension
Prostacyclin probably leads to higher improvement in WHO functional class compared with control (moderate certainty).
1 finding from 1 review
Headache+ · pulmonary arterial hypertension
1 finding from 1 review
Improvement in WHO functional class · pulmonary arterial hypertension
Selexipag showed no clear difference in improvement in WHO functional class compared with placebo (moderate certainty).
1 finding from 1 review
Six‐minute walk distance · pulmonary arterial hypertension
1 finding from 1 review
All‐cause mortality · pulmonary arterial hypertension
1 finding from 1 review
Dyspnea · pulmonary arterial hypertension
1 finding from 1 review
Headache+ · pulmonary arterial hypertension
1 finding from 1 review
Six‐minute walk distance · pulmonary arterial hypertension
1 finding from 1 review
All‐cause mortality · pulmonary arterial hypertension
Prostacyclin probably leads to lower mortality compared with control (moderate certainty).
1 finding from 1 review
Dyspnea · pulmonary arterial hypertension
1 finding from 1 review
Quality of life · pulmonary arterial hypertension
1 finding from 1 review
Intervention not reported
Change in Exercise Capacity (6MWD) · Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
1 finding from 1 review
Intervention not reported
Mortality · Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
The intervention showed no clear difference in mortality (low certainty).
1 finding from 1 review
Intervention not reported
Improvement in WHO Functional Class · Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
The intervention showed no clear difference in improvement in WHO Functional Class (low certainty).
1 finding from 1 review
Intervention not reported
Serious Adverse Events (Participants with one or more event) · Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
It is very uncertain whether the intervention changes serious Adverse Events (Participants with one or more event) (very low certainty).
1 finding from 1 review